Stockscreener 앱 받기
96.56
0.26%
0.25
시간 외 거래:
96.57
0.010
+0.01%
전일 마감가:
$96.31
열려 있는:
$96.56
하루 거래량:
11.48M
Relative Volume:
1.31
시가총액:
$242.49B
수익:
$63.17B
순이익/손실:
$12.15B
주가수익비율:
53.64
EPS:
1.8
순현금흐름:
$14.84B
1주 성능:
-4.14%
1개월 성능:
-11.17%
6개월 성능:
-26.40%
1년 성능:
-5.10%
1일 변동 폭
$95.42
$97.29
1주일 범위
$94.48
$100.77
52주 변동 폭
$94.48
$134.63
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
MRK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Jim Cramer Says Merck & Co., Inc. (MRK) Is ‘Just Way Too Hated’ - Insider Monkey
Merck & Co., Inc. (NYSE:MRK) Trading Down 0.6%What's Next? - MarketBeat
Stocks Flash: Biggest Recent Disappointment (Merck & Co Inc., MRK) and Biggest Bright Spot (Dell Technologies Inc, DELL) - Elliott Wave International
Is Merck & Co., Inc. (MRK) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
Braun Stacey Associates Inc. Lowers Stock Holdings in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
AMG National Trust Bank Sells 5,505 Shares of Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Aljian Capital Management LLC Makes New Investment in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Shares Sold by TrinityPoint Wealth LLC - MarketBeat
Swiss National Bank Has $853.74 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Shares Bought by Thrivent Financial for Lutherans - MarketBeat
Concord Asset Management LLC VA Has $5.08 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Mutual of America Capital Management LLC Decreases Stake in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Mizuho Securities USA LLC Sells 53,617 Shares of Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Stock Holdings Decreased by Natixis Advisors LLC - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Lowers Stock Position in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Kentucky Retirement Systems Has $20.05 Million Stake in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Intellectus Partners LLC Acquires Shares of 6,426 Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co. Inc. stock underperforms Friday when compared to competitors - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Shares Down 2.4%Here's What Happened - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Shares Sold by Archer Investment Corp - MarketBeat
Empowered Funds LLC Buys 147,267 Shares of Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Sheaff Brock Investment Advisors LLC Has $13.94 Million Position in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Signature Estate & Investment Advisors LLC Acquires 48,807 Shares of Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (NYSE:MRK) is Cornercap Investment Counsel Inc.'s 4th Largest Position - MarketBeat
Merck: CHMP gives green light for Keytruda in pleural mesothelioma - Marketscreener.com
Wolfe Research Initiates Coverage on Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Shares Sold by CIBC Asset Management Inc - MarketBeat
Merck & Co. Inc. stock outperforms competitors despite losses on the day - MarketWatch
Merck & Co. Jumps Into PD-1/VEGF Bispecific Race With LaNova Deal - Scrip
Merck & Co., Inc. (NYSE:MRK) Stock Price Down 0.3%Time to Sell? - MarketBeat
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd - Marketscreener.com
ING Groep NV Sells 281,509 Shares of Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Lifeworks Advisors LLC Raises Holdings in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Ferguson Wellman Capital Management Inc. Grows Stock Position in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck: acquires exclusive license from LaNova Medicines - Marketscreener.com
Merck & Co., Inc. (NYSE:MRK) Shares Sold by Curi RMB Capital LLC - MarketBeat
Merck Hops Onto PD-1/VEGF Train, Committing up to $3B Plus in LaNova Deal - BioSpace
Merck: Keytruda’s Sales Projections Outweigh Competitive And Patent Risks (NYSE:MRK) - Seeking Alpha
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova - Reuters
KBC Group NV Sells 884,248 Shares of Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck stock on watch after cancer drug deal (NYSE:MRK) - Seeking Alpha
5 Dow Jones Giants With High Upside Potential and Rock-Solid Financial Health - Investing.com
Merck to Participate in the Jefferies London Healthcare Conference - Business Wire
Merck (MRK) Enters into Exclusive Global License for LM-299 - StreetInsider.com
Merck Inks $3.3B Bispecific Antibody Deal with LaNova Medicines | MRK Stock News - StockTitan
Merck Snags Chinese Cancer Drug For Up to $3.3 Billion - BNN Bloomberg
GSA Capital Partners LLP Invests $1.44 Million in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Shares Down 0.4%Should You Sell? - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Shares Bought by Main Street Financial Solutions LLC - MarketBeat
Oppenheimer & Co. Inc. Buys 6,503 Shares of Merck & Co., Inc. (NYSE:MRK) - MarketBeat
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.02%
0.78%
자본화:
|
볼륨(24시간):